RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Glioblastoma: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Novel therapies for glioblastoma.
Gupta Sneha R et al., Current opinion in neurology (20 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42895289/
- 2.
Association of neuropathological Ki-67 labelling index with glioblastoma patterns of failure and survival outcome.
Ryan Lim-Yip, European Society of Radiology (19 October 2026)
https://doi.org/10.26044/ranzcr2026/c-405
- 3.
Contouring of Glioblastoma Across New Zealand: A National Survey – The COG ANZ Study
Seoungyeun Han, European Society of Radiology (19 October 2026)
https://doi.org/10.26044/ranzcr2026/c-49
- 4.
Biomarker-guided treatment strategies for patients with gliomas in clinical practice.
Le Rhun Emilie et al., Neuro-oncology (19 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42895284/
- 5.
When extended metabolites profiling helps the prediction of local relapse in glioblastoma: a retrospective study using MRI and MRSI.
Labriji Wafae et al., The British journal of radiology (19 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42895285/
Clinical Trials : Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab
NCT06816927 · Recruiting · Phase 2 · Duke University
Ages 18 and over
https://clinicaltrials.gov/study/NCT06816927
- 2.
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
NCT06926075 · Recruiting · Phase 1 / Phase 2 · Filamon LTD
Ages 18 and over
https://clinicaltrials.gov/study/NCT06926075
- 3.
Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma
NCT07100730 · Recruiting · Phase 3 · Telix Pharmaceuticals (Innovations) Pty Limited
Ages 18 and over
https://clinicaltrials.gov/study/NCT07100730
- 4.
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
NCT05843253 · Recruiting · Phase 2 · Nationwide Children's Hospital
Ages 12 Months to 39
https://clinicaltrials.gov/study/NCT05843253
- 5.
Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma
NCT06132438 · Recruiting · Phase 1 · Charlotte Lemech
Ages 18 to 100
https://clinicaltrials.gov/study/NCT06132438
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Glioblastoma
Glioblastoma is an aggressive cancer that starts in the supporting glial cells of the brain. It can cause headaches, seizures, weakness and changes in thinking or personality, depending on where it grows. Treatment usually combines surgery, radiotherapy and chemotherapy, along with care to manage symptoms. Clinical trials of new therapies are ongoing.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
PURPOSE OF REVIEW: Glioblastoma is the most aggressive and treatment-resistant primary brain tumor in adults. Given its clinical severity and biological complexity, research efforts are focused on understanding and targeting intratumoral heterogeneity, adaptive resistance, drug delivery barriers, and the immunosuppressive tumor microenvironment. This review highlights emerging therapeutic approaches for the treatment of glioblastoma including advances in radiation planning, molecularly targeted therapy, immunotherapy, blood-brain barrier modulation, and neuronal signaling. RECENT FINDINGS: Radiation therapy remains a cornerstone of glioblastoma treatment, and advances in image-guided planning are being developed to refine treatment margins and improve tolerability without compromising efficacy. Blood-brain barrier permeability is being improved through device-assisted approaches, including focused ultrasound in combination with systemic therapies. Molecularly targeted and immunotherapeutic approaches continue to be evaluated, increasingly with biomarker-informed strategies to optimize patient selection. In parallel, drug repurposing, neuronal modulation, and metabolic interventions have shown promising preclinical and retrospective signals and are moving towards prospective studies. Interventions to improve quality of life are also underway with early palliative care showing significant impact for patients with glioblastoma. SUMMARY: As the field moves towards tailored and precision-guided approaches, combination strategies remain central to addressing the multiple mechanisms by which glioblastoma evades treatment.
Common Questions
What is Glioblastoma?
Glioblastoma is an aggressive cancer that starts in the supporting glial cells of the brain. It can cause headaches, seizures, weakness and changes in thinking or personality, depending on where it grows. Treatment usually combines surgery, radiotherapy and chemotherapy, along with care to manage symptoms. Clinical trials of new therapies are ongoing.
How many clinical trials are available for Glioblastoma?
RareWays currently indexes 1735 clinical trials for Glioblastoma, of which 267 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Glioblastoma come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Glioblastoma.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.